In Which Patients with Sarcoidosis Is FDG PET/CT Indicated?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Mar 28

PMID 32213991

Citations 25

Authors

Ruth G M Keijsers

Jan C Grutters

Affiliations

Soon will be listed here.

Abstract

Sarcoidosis is a granulomatous disease of which the etiology remains unknown. The diverse clinical manifestations may challenge clinicians, particularly when conventional markers are inconclusive. From various studies, it has become clear that fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT aids in sarcoidosis care. In this article, an update on FDG PET/CT in sarcoidosis is provided. The use of FDG PET/CT in the diagnostic process of sarcoidosis is explained, especially in determining treatable inflammatory lesions in symptomatic patients with indecisive conventional tests. Furthermore, FDG PET/CT for evaluating the potential benefit of additional inflammatory treatment is described and its use in cardiac sarcoidosis is highlighted.

Citing Articles

Insights Into Hepatic Sarcoidosis: Analysis of Histological Patterns, Hepatic Complications and Therapeutic Approaches.

Horst L, Zimmermann K, Lutz J, Weidemann S, Luth S, Lohse A Liver Int. 2025; 45(3):e70037.

PMID: 39969799 PMC: 11837985. DOI: 10.1111/liv.70037.

Carcinoma Breast Presenting with Concurrent Extensive Lymph Nodal Sarcoidosis.

Sharma S, Singh V, Gambhir S, Ora M Indian J Nucl Med. 2025; 39(4):323-324.

PMID: 39790814 PMC: 11708804. DOI: 10.4103/ijnm.ijnm_66_23.

[Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024].

Sterniste G, Hackner K, Moazedi-Furst F, Grasl M, Idzko M, Shao G Wien Klin Wochenschr. 2024; 136(Suppl 17):669-687.

PMID: 39382646 PMC: 11464578. DOI: 10.1007/s00508-024-02444-z.

Meta-analysis of [F]FDG-PET/CT in pulmonary sarcoidosis.

Donnelly R, McDermott M, McManus G, Franciosi A, Keane M, McGrath E Eur Radiol. 2024; .

PMID: 39044038 DOI: 10.1007/s00330-024-10949-4.

Cardiopulmonary exercise testing complements both spirometry and nuclear imaging for assessing sarcoidosis stage and for monitoring disease activity.

Torregiani C, Reale M, Confalonieri M, Dore F, Crisafulli C, Baratella E Sarcoidosis Vasc Diffuse Lung Dis. 2024; 41(1):e2024017.

PMID: 38567559 PMC: 11008331. DOI: 10.36141/svdld.v41i1.15125.

References

Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M . Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med. 1997; 156(1):255-9. DOI: 10.1164/ajrccm.156.1.9612011. View

Mostard R, Verschakelen J, van Kroonenburgh M, Nelemans P, Wijnen P, Voo S . Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med. 2012; 107(3):439-47. DOI: 10.1016/j.rmed.2012.11.011. View

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G . The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012; 53(2):241-8. DOI: 10.2967/jnumed.111.090662. View

Malkovsky M, Loveland B, North M, Asherson G, Gao L, Ward P . Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987; 325(6101):262-5. DOI: 10.1038/325262a0. View

Maturu V, Agarwal R, Aggarwal A, Mittal B, Bal A, Gupta N . Dual-time point whole-body 18F-fluorodeoxyglucose PET/CT imaging in undiagnosed mediastinal lymphadenopathy: a prospective study of 117 patients with sarcoidosis and TB. Chest. 2014; 146(6):e216-e220. DOI: 10.1378/chest.14-1827. View

Teirstein A, Machac J, Almeida O, Lu P, Padilla M, Iannuzzi M . Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007; 132(6):1949-53. DOI: 10.1378/chest.07-1178. View

Kalkanis A, Kalkanis D, Polychronopoulos V, Judson M . Detection of sarcoidosis associated fasciitis by uptake on a FDG PET scan: a novel finding. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30(2):143-5. View

Lower E, Smith J, Martelo O, Baughman R . The anemia of sarcoidosis. Sarcoidosis. 1988; 5(1):51-5. View

Lewis P, Salama A . Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994; 35(10):1647-9. View

10.

Scholtens A, Verberne H, Budde R, Lam M . Additional Heparin Preadministration Improves Cardiac Glucose Metabolism Suppression over Low-Carbohydrate Diet Alone in ¹⁸F-FDG PET Imaging. J Nucl Med. 2015; 57(4):568-73. DOI: 10.2967/jnumed.115.166884. View

11.

Simonen P, Lehtonen J, Kandolin R, Schildt J, Marjasuo S, Miettinen H . F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol. 2015; 116(10):1581-5. DOI: 10.1016/j.amjcard.2015.08.025. View

12.

Slart R, Glaudemans A, Lancellotti P, Hyafil F, Blankstein R, Schwartz R . A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the.... J Nucl Cardiol. 2017; 25(1):298-319. DOI: 10.1007/s12350-017-1043-4. View

13.

Sharma P, Smith I, Maguire G, Stewart S, Shneerson J, Brown M . Clinical value of ACE genotyping in diagnosis of sarcoidosis. Lancet. 1997; 349(9065):1602-3. DOI: 10.1016/S0140-6736(05)61631-5. View

14.

Silverstein E, Friedland J, LYONS H, GOURIN A . Elevation of angiotensin-converting enzyme in granulomatous lymph nodes and serum in sarcoidosis: clinical and possible pathogenic significance. Ann N Y Acad Sci. 1976; 278:498-513. DOI: 10.1111/j.1749-6632.1976.tb47062.x. View

15.

Rothkrantz-Kos S, van Dieijen-Visser M, Mulder P, Drent M . Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003; 49(9):1510-7. DOI: 10.1373/49.9.1510. View

16.

Osborne M, Hulten E, Singh A, Waller A, Bittencourt M, Stewart G . Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2013; 21(1):166-74. DOI: 10.1007/s12350-013-9828-6. View

17.

Bejerano C, Blanco R, Gonzalez-Vela C, Aguero R, Carril J, Gonzalez-Gay M . Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab. Clin Exp Rheumatol. 2012; 30(1 Suppl 70):S94-7. View

18.

Klech H, Kohn H, Kummer F, MOSTBECK A . Assessment of activity in Sarcoidosis. Sensitivity and specificity of 67Gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations. Chest. 1982; 82(6):732-8. DOI: 10.1378/chest.82.6.732. View

19.

Hollinger W, Staton Jr G, Fajman W, Gilman M, Pine J, Check I . Prediction of therapeutic response in steroid-treated pulmonary sarcoidosis. Evaluation of clinical parameters, bronchoalveolar lavage, gallium-67 lung scanning, and serum angiotensin-converting enzyme levels. Am Rev Respir Dis. 1985; 132(1):65-9. DOI: 10.1164/arrd.1985.132.1.65. View

20.

Studdy P, Lapworth R, Bird R . Angiotensin-converting enzyme and its clinical significance--a review. J Clin Pathol. 1983; 36(8):938-47. PMC: 498427. DOI: 10.1136/jcp.36.8.938. View